Research programme: protectans - Cleveland BioLabs

Drug Profile

Research programme: protectans - Cleveland BioLabs

Alternative Names: CBLB 613; Pifithrin-mu

Latest Information Update: 20 Jan 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cleveland BioLabs
  • Class Proteins; Small molecules
  • Mechanism of Action Stem cell stimulants; Tumour suppressor protein p53 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Chemotherapy-induced damage; Radiation injuries

Most Recent Events

  • 17 Jan 2012 Preclinical development is ongoing
  • 11 Jun 2009 Preclinical development is ongoing
  • 07 Aug 2006 Preclinical findings have been added to the adverse events and Cancer pharmacodynamics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top